Starling Oncology (NASDAQ:STLN) reported quarterly earnings results on November 05, 2026 that fell short of analyst expectations.
At publication ·
Starling Oncology (NASDAQ:STLN) · earnings miss
At a glance
Starling Oncology (NASDAQ:STLN) reported quarterly earnings results on November 05, 2026 that fell short of analyst expectations.
The company reported earnings per share of $-0.13, missing the consensus estimate of $-0.05 by $0.08 per share. Revenue came in at $169.8M, beating the estimate of $168.6M.
Starling Oncology's stock moved following the earnings release.
Missing analyst estimates puts pressure on a stock as investors reassess their growth assumptions. The market's reaction to an earnings miss depends heavily on the magnitude of the shortfall, the company's forward guidance, and whether the miss was driven by temporary or structural factors.
The 160% miss relative to consensus estimates is a notable deviation. Earnings surprises of this magnitude often trigger analyst revisions and can influence institutional positioning in the weeks following the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Starling Oncology should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.
| Quarter | EPS Actual | EPS Est. | Surprise |
|---|---|---|---|
| Q3 (Nov 2026) | $-0.13 | $-0.05 | -160.0% |
| Q2 (Aug 2026) | $-0.08 | N/A | |
| Q2 (Aug 2026) | $-0.08 | $-0.06 | -33.3% |
Related Tools: Earnings Calendar | View STLN Stock Page
Check the latest earnings dates on our STLN earnings page or the Earnings Calendar.
See the full Q3 results including EPS actual vs estimate on our STLN earnings page.
Current market data
NASDAQ · STLN
